Manfidokimab vs Rademikibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
Manfidokimab
Developed by Akeso
NCT06383468 · Phase 3 · status unknown
This Phase 3 trial randomly assigned adults with moderate-to-severe atopic dermatitis to manfidokimab (AK120) or placebo, both delivered by subcutaneous injection, under quadruple-blind conditions, with the proportion of patients achieving EASI-75 (75% improvement in eczema severity) at week 16 as the primary endpoint. No results have been posted, so this remains a well-designed, adequately sized, blinded, placebo-controlled trial whose findings are not yet known.
Next expected readout: July 2027 · NCT06767540 (registry estimate)
No aligned efficacy figure on record for this race.
Rademikibart
Developed by Connect Biopharma and partners
NCT05017480 · Phase 2 · completed
SEASIDE CHINA was a randomized, double-blind, placebo-controlled Phase 2 trial in 330 Chinese adults and adolescents with moderate to severe atopic dermatitis, randomized 2:1 to rademikibart or placebo for 16 weeks. The primary endpoint was vIGA 0 or 1 with a reduction of at least 2 points at week 16. It was reached by 29.0% on rademikibart vs 5.9% on placebo (P<0.001), so the primary was met. Source: the SEASIDE CHINA paper (Br J Dermatol 2026).
Reported efficacy
Investigator Global Assessment (IGA) (0-1) (Baseline to Week16): vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026). (met)
Result source: NCT05017480
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Manfidokimab | Rademikibart |
|---|---|---|
| EASI-75 | —Trial running · NCT06767540 | 58.6% vs 22.6%+36 vs placeboNCT05017480 |
| IGA 0/1 with 2-point improvement | —Trial running · NCT06767540 | —Not posted · NCT06477835 |
| EASI-90 | —Trial running · NCT06767540 | 33.4% vs 6.4%+27 vs placeboNCT05017480 |
| EASI, % change | —Trial running · NCT06767540 | -57.6% vs -39.7%−17.9 vs placeboNCT044447522 other results
|
EASI-75
- Manfidokimab
- —Trial running · NCT06767540
- Rademikibart
- 58.6% vs 22.6%+36 vs placeboNCT05017480
IGA 0/1 with 2-point improvement
- Manfidokimab
- —Trial running · NCT06767540
- Rademikibart
- —Not posted · NCT06477835
EASI-90
- Manfidokimab
- —Trial running · NCT06767540
- Rademikibart
- 33.4% vs 6.4%+27 vs placeboNCT05017480
EASI, % change
- Manfidokimab
- —Trial running · NCT06767540
- Rademikibart
- -57.6% vs -39.7%−17.9 vs placeboNCT04444752
2 other results
- -63.0% vs -39.7% NCT04444752
- -63.5% vs -39.7% NCT04444752
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Manfidokimab: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Manfidokimab: 0 of 4 rows · Rademikibart: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Rademikibart |
|---|---|
| Dropout rate | 4.6%300mg Q2Wa NCT05017480 · Phase 2 show 6 more results—300mg Q2W NCT05017480 · Phase 2 —300mg Q4W NCT05017480 · Phase 2 —300mg Q2W NCT05017480 · Phase 2 19.3%150 Q2W NCT04444752 · Phase 2 · registry result, not featured evidence 21.1%300 Q2W NCT04444752 · Phase 2 · registry result, not featured evidence 10.7%300 Q4W NCT04444752 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.5%300mg Q2Wa NCT05017480 · Phase 2 show 6 more results—300mg Q2W NCT05017480 · Phase 2 —300mg Q4W NCT05017480 · Phase 2 —300mg Q2W NCT05017480 · Phase 2 1.8%150 Q2W NCT04444752 · Phase 2 · registry result, not featured evidence 0%300 Q2W NCT04444752 · Phase 2 · registry result, not featured evidence 0%300 Q4W NCT04444752 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0.5%300mg Q2Wa NCT05017480 · Phase 2 show 6 more results0.9%300mg Q2W NCT05017480 · Phase 2 2.7%300mg Q4W NCT05017480 · Phase 2 7.1%300mg Q2W NCT05017480 · Phase 2 1.8%150 Q2W NCT04444752 · Phase 2 · registry result, not featured evidence 0%300 Q2W NCT04444752 · Phase 2 · registry result, not featured evidence 3.6%300 Q4W NCT04444752 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 300mg Q2Wa atopic dermatitis 10.5% (placebo 17.1%) hyperlipidaemia 10.5% (placebo 5.4%) hyperuricemia 9.6% (placebo 4.5%) NCT05017480 · Phase 2 show 6 more results300mg Q2W covid-19 33.6% (placebo 0%) atopic dermatitis 12.4% (placebo 17.1%) upper respiratory infection 10.6% (placebo 6.3%) NCT05017480 · Phase 2 300mg Q4W covid-19 30.4% (placebo 0%) atopic dermatitis 24.1% (placebo 17.1%) upper respiratory infection 10.7% (placebo 6.3%) NCT05017480 · Phase 2 300mg Q2W covid-19 24.7% (placebo 0%) upper respiratory infection 17.6% (placebo 6.3%) atopic dermatitis 16.5% (placebo 17.1%) NCT05017480 · Phase 2 150 Q2W dermatitis atopic 12.3% (placebo 14.3%) covid-19 7% (placebo 7.1%) urinary tract infection 7% (placebo 1.8%) NCT04444752 · Phase 2 · registry result, not featured evidence 300 Q2W dermatitis atopic 8.8% (placebo 14.3%) nasopharyngitis 5.3% (placebo 7.1%) conjunctivitis 3.5% (placebo 0%) NCT04444752 · Phase 2 · registry result, not featured evidence 300 Q4W dermatitis atopic 25% (placebo 14.3%) headache 7.1% (placebo 0%) nausea 5.4% (placebo 0%) NCT04444752 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Rademikibart
show 3 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Manfidokimab's landscape · Rademikibart's landscape